1-8 of 8
Joseph R. Mace
Close
Sort by
Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

Saad Z. Usmani, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael E. O'Dwyer, Aurore Perrot, Chris P. Venner, Katja Weisel, Joseph R. Mace, Noopur S. Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Rian Van Rampelbergh, Brenda Tromp, Maria Delioukina, Thierry Facon
Journal: Blood
Blood (2021) 138 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2021-146940
Published: 2021
Journal Articles

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

Aurore Perrot, Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael E. O'Dwyer, Chris P. Venner, Katja Weisel, Joseph R. Mace, Noopur S. Raje, Mourad Tiab, Magaret Macro, Laurent Frenzel, Xavier Leleu, Kevin Liu, John Fastenau, Katharine S. Gries, Kai Fai Ho, Pankaj Mistry, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Z. Usmani
Journal: Blood
Blood (2021) 138 (Supplement 1): 1655.
https://doi.org/10.1182/blood-2021-144421
Published: 2021
Journal Articles

Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Aurore Perrot, Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael E. O'Dwyer, Chris P. Venner, Katja Weisel, Joseph R. Mace, Noopur S. Raje, Mourad Tiab, Magaret Macro, Laurent Frenzel, Xavier Leleu, Kevin Liu, John Fastenau, Katharine S. Gries, Kai Fai Ho, Pankaj Mistry, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Z. Usmani
Journal: Blood
Blood (2021) 138 (Supplement 1): 4095.
https://doi.org/10.1182/blood-2021-150369
Published: 2021
Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Thierry Facon, Shaji K. Kumar, MD, Torben Plesner, MD DSc, Robert Z. Orlowski, MD PhD, Philippe Moreau, Nizar Bahlis, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Hareth Nahi, MD PhD, Cyrille Hulin, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Hartmut Goldschmidt, MD, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, MD FRCPC, Katja Weisel, MD, Joseph R. Mace, Tahamtan Ahmadi, Christopher Chiu, PhD, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, MD, Ming Qi, MD PhD, Saad Z. Usmani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): LBA-2.
https://doi.org/10.1182/blood-2018-120737
Published: 2018
Journal Articles

A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion

Jesus G. Berdeja, MD, Tara B. Gregory, MD, Edward Faber, Jeffrey Matous, MD, Lowell Hart, MD, Joseph R. Mace, MD, Edward R. Arrowsmith, MD MPH, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4530.
https://doi.org/10.1182/blood.V128.22.4530.4530
Published: 2016
Journal Articles

A Phase I/II Study of the Combination of Panobinostat (PAN) and Carfilzomib (CFZ) in Patients (pts) with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Comparison of Two Expansion Cohorts

Jesus G. Berdeja, MD, Tara B. Gregory, MD, Edward A. Faber, DO, Jeffrey V. Matous, MD, Lowell L. Hart, MD, Joseph R. Mace, MD, James D. Peyton, MD, James H. Essell, MD, Edward R. Arrowsmith, MD MPH, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1825.
https://doi.org/10.1182/blood.V126.23.1825.1825
Published: 2015
Journal Articles

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Guillermo Garcia-Manero, MD, Ellen K. Ritchie, MD, Katherine Walsh, MD, Michael Savona, MD, Patricia Kropf, MD, Casey O'Connell, MD, Raoul Tibes, MD, Naval G. Daver, MD, Elias Jabbour, MD, Scott Lunin, MD, Todd L. Rosenblat, MD, Karen Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Joseph R Mace, MD, Nikolai A. Podoltsev, MDPhD, Jesus G. Berdeja, MD, Jean-Pierre Issa, MD, Woonbok Chung, PhD, Sue Naim, Pietro Taverna, PhD, Yong Hao, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2014) 124 (21): 529.
https://doi.org/10.1182/blood.V124.21.529.529
Published: 2014
Journal Articles

A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)

Jesus Berdeja, MD, Michael Savona, MD, Joseph R Mace, MD, Lowell Hart, MD, James Essell, MD, Rami Owera, MD, Edward Arrowsmith, MD, MPH, Ian Flinn, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1937.
https://doi.org/10.1182/blood.V122.21.1937.1937
Published: 2013